Batoprotafib
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM) . Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
Product Specifications
CAS Number
1801765-04-7
Product Name Alternative
TNO155
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Phosphatase; SHP2
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/batoprotafib.html
Purity
99.41
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2
Molecular Formula
C18H24ClN7OS
Molecular Weight
421.95
Precautions
H315, H319, H320
References & Citations
[1]TNO155: SHP2 inhibitor|[2]Liu C, et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27 (1) :342-354.|[3]Weiss A, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12 (6) :1500-1517.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
